首页工具

Fedratinib

规格	价格/CNY		数量
2 mg	￥ 265	现货
5 mg	￥ 379	现货
10 mg	￥ 543	现货
25 mg	￥ 773	现货
100 mg	￥ 1,198	现货
200 mg	￥ 1,995	现货
500 mg	￥ 4,280	现货
1 mL * 10 mM (in DMSO)	￥ 481	现货

相关产品

产品描述	Fedratinib (TG-101348) is a JAK2 inhibitor that is selective, ATP-competitive, and orally active, inhibiting JAK2 and JAK2V617F kinases (IC50=3 nM). Fedratinib induces apoptosis in tumor cells and may be used in myeloproliferative diseases.
靶点活性	FLT3:15 nM (cell free), JAK2 (V617F):3 nM (cell free), JAK2:3 nM (cell free), RET:48 nM (cell free)
体外活性	方法：人成红细胞白血病细胞 HEL 和 Ba/F3 JAK2V617F 细胞用 Fedratinib (0-30 µM) 处理 72 h，使用 XTT assay 检测细胞增殖。结果：Fedratinib 抑制了携带 JAK2V617F 突变的 HEL 细胞系以及表达人 JAK2V617F (Ba/F3 JAK2V617F) 的鼠前 B 细胞系的增殖，两种细胞系的 IC50 值分别为 305 nM 和 270 nM。[1] 方法：人骨髓间充质干细胞 hMSC-TERT 用 Fedratinib (3 µM) 处理 10 天，进行碱性磷酸酶 (ALP) 染色检测成骨分化。结果：Fedratinib 处理的 hMSC-TERT 细胞表现出 ALP 产生的显著减少。与对照细胞相比，成骨细胞分化诱导后第 10 天的 ALP 活性测量值降低。Fedratinib 对 hMSC-TERT 细胞的活力没有产生显著影响。[2]
体内活性	方法：为研究对已建立的真性红细胞增多症的疗效，将 Fedratinib (60-120 mg/kg) 灌胃给药给 C57BL/6 小鼠骨髓移植模型，每天两次，持续 42 天。结果：在接受治疗的动物中，红细胞压积和白细胞计数在统计学上显著降低，髓外造血的减少/消除呈剂量依赖性，至少在某些情况下，有证据表明骨髓纤维化减轻。[1]
激酶实验	IC50 values for TG101348 are determined commercially using the InVitrogen kinase profiling service for a 223 kinase screen that included JAK2 and JAK2V617F or Carna Biosciences for the screen of all Janus kinase family members including JAK1 and Tyk2. ATP concentration is set to approximately the Km value for each kinase [1].
细胞实验	Cells were treated with DMSO and increasing concentrations of inhibitor for 4 hr in RPMI-1640 before collected in 13 Cell Lysis Buffer, containing 1 mM PMSF, and protease inhibitor cocktail tablets. Protein lysates were quantified with BCA assay. Similar protein amounts were mixed with Laemmli sample buffer plus b-mercaptoethanol, boiled for 5 min, and separated on a 4%–15% Tris-HCl gradient electrophoresis gel. Gels were blotted onto a 0.45 mm nitrocellulose membrane, which was blocked in 5% nonfat dry milk and incubated with primary antibodies in either blocking solution or 5% BSA. The membranes were subsequently incubated with a mixture of donkey anti-rabbit IgG conjugated with infrared fluorophore (700 nm emission) and goat anti-mouse IgG conjugated with infrared fluorophore (800 nm emission). Following washing with PBS, the membranes were scanned on an Odyssey scanner to detect total (red) and phospho-STAT5 (green) proteins [1].
动物实验	The murine BM transplant model was generated and analyzed exactly as previously described. Briefly, C57BL/6 mice were intravenously injected with 1×10^6 whole bone marrow expressing JAK2V617F. Full development of disease was assessed with differential peripheral blood counts at day 26 after bone marrow transplantation. TG101348 was administered by oral gavage twice daily (b.i.d.) at 60 mg/kg, 120 mg/kg, or placebo from day 28 on for 42 days. Differential blood counts were assessed by retro-orbital nonlethal eye bleeds using EDTA glass capillary tubes before study initiation, during the study, and at study endpoints. C57/Bl6 mice were sacrificed at study endpoint or at times indicated based on an IUCAC-approved protocol that includes assessment of morbidity by > 10% loss of weight, scruffy appearance, lethargy, and/or splenomegaly extending across the midline. For histopathology, tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin or, to assess for fibrosis, stained with reticulin. Images of histological slides were obtained on a Nikon Eclipse E400 microscope equipped with a SPOT RT color digital camera model 2.1.1. Images were analyzed in Adobe Photoshop 6.0. For flow cytometry, cells were washed in PBS, washed in 2% fetal bovine serum, blocked with Fc-Block for 10 min on ice, and stained with monoclonal antibodies in PBS and 2% FCS for 30 min on ice. Antibodies used were allophycocyanin (APC)-conjugated ter119, Gr-1, CD4, and B220 and phycoerythrin (PE)-conjugated, Mac1, CD8 (all 1:200), and CD71(1:100) rat anti-mouse. After washing, cells were resuspended in PBS and 2% FCS containing 0.5 mg/ml 7-amino-actinomycin D (7-AAD) to allow discrimination of nonviable cells. Flow cytometry was performed on a FACS Calibur cytometer, at least 10,000 events were acquired, and data were analyzed using FloJo software.The results are presented as graphs and representative dot plots of viable cells selected on the basis of scatter and 7-AAD staining [1].

别名	TG-101348, SAR 302503
化合物与蛋白结合的复合物	JAK2 JH1 in complex with Fedratinib
分子量	524.68
分子式	C27H36N6O3S
CAS No.	936091-26-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 50 mg/mL (95.3 mM)

H2O: < 1 mg/mL (insoluble or slightly soluble)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9059 mL	9.5296 mL	19.0592 mL	47.6481 mL
	5 mM	0.3812 mL	1.9059 mL	3.8118 mL	9.5296 mL
	10 mM	0.1906 mL	0.953 mL	1.9059 mL	4.7648 mL
	20 mM	0.0953 mL	0.4765 mL	0.953 mL	2.3824 mL
	50 mM	0.0381 mL	0.1906 mL	0.3812 mL	0.953 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20. 2. AlMuraikhi N, et al. JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells. Molecules. 2021 Jan 25;26(3):606. 3. Pardanani A, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 1;29(7):789-96. 4. Zeng F, Chen H, Chen L, et al. An Autocrine Circuit of IL-33 in Keratinocytes is Involved in the Progression of Psoriasis[J]. Journal of Investigative Dermatology. 2020

文献引用

1. Qian Y, Arellano G, Ifergan I, et al. ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Reports. 2021, 36(8): 109602. 2. Ge H, Wang C, Tian C, et al. Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms. Biomedicine & Pharmacotherapy. 2022, 156: 113884 3. Zeng F, Chen H, Chen L, et al An Autocrine Circuit of IL-33 in Keratinocytes is Involved in the Progression of Psoriasis. Journal of Investigative Dermatology. 2020 4. Si H, Wang J, He R, et al. Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor. Frontiers in oncology. 2021, 11: 807200-807200. 5. Qin R, Wang T, He W, et al.Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL.Cell Communication and Signaling.2023, 21(1): 27.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +